People with mitochondrial disease (mito) can respond to medicines in different ways. It is important to talk to a health professional before making changes to your medications. They can help you understand any risks related to mito.
Important medicines for primary mitochondrial disease
International Mito Patients (IMP) have 2 lists. These are:
- medicines considered safe for people with mito
- medicines that should be used with caution or avoided.
A group of doctors, pharmacists, and scientists looked over past versions and updated the list. You might find it helpful to print a copy and share it with your health care team. Always check with a health professional before taking any medications to reduce your risk.
Important medicines for Leber Hereditary Optic Neuropathy (LHON)
In addition to the IMP list for primary mitochondrial disease, a specific list has been created for people with LHON.
If you have LHON or a family history, this list includes:
- medicines that should be used with caution or avoided
- risk factors that might cause cell stress.
LHON Collective has a list of medications that should be used carefully by people with LHON. You might find it helpful to print a copy and share it with your health care team. Always speak to a health professional before taking any medications to reduce your risk.
Access the publicly available scientific publication "Safety of drug use in patients with a primary mitochondrial disease: An international Delphi-based consensus."
Please note that the scientific publication "Toxic medications in Leber's hereditary optic neuropathy" is not publicly available, but Mito Foundation has provided a downloadable version.
Disclaimer: Resources provided by the Australian Mitochondrial Disease Foundation Limited (Mito Foundation), offers general information and is not a substitute for medical advice. It is essential to assess the suitability of the content for your individual circumstances and make decisions based on your medical condition. The information’s accuracy is subject to change, and we do not guarantee ongoing currency or availability. While efforts are made to ensure accuracy, Mito Foundation is not obligated to provide updated information. The copyright for this document and its content belongs to, or is licensed to, Mito Foundation, and reproduction without prior written consent is prohibited.
Author: Mito Foundation
Version: 2
Date reviewed: Monday 24 February 2025
